RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024March 19, 2024 - Big Pharma AstraZeneca acquires Canadian Phase 2 radiopharmaceutical company Fusion Pharmaceuticals for US$2.4 Billion
Fusion CEO John Valliant said in a statement that the acquisition will combine “Fusion’s expertise and capabilities in radioconjugates” with AstraZeneca’s “leadership in small molecules and biologics engineering.”
https://www.biospace.com/article/astrazeneca-buys-fusion-in-potential-2b-deal-joins-radiopharma-buying-spree/
The issue is that AstraZeneca is one of those Big Pharma company's who have a vested interest in India's small molecule development industry and is being impacted by the US IRA, which favors novel single indication biologics with 13 years of market exclusivity on approval over small molecule entities.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35939126